Home » Topics » Disease categories and therapies » Dental

Dental
RSS

Acacia Pharma initiates phase II study of locally administered xerostomia drug

July 25, 2011

PMX-30063 shows activity against oral mucositis in animal study

May 24, 2011

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

March 21, 2011

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Feb. 16, 2011

Oragenics plans second phase I trial of SMaRT replacement therapy

Feb. 2, 2011

Strativa launches Oravig in U.S. for oropharyngeal candidiasis

Aug. 25, 2010

Access Pharma and BioScrip sign MuGard distribution agreement

July 22, 2010

Sanofi-aventis and Novalar submit OraVerse MAA in five European countries

July 16, 2010

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

April 20, 2010

BioDelivery Sciences presents update on BEMA Buprenorphine

March 3, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...